Monthly Archives: November 2017

Takeaways from Recent Data on Superficial Femoral Artery

  Superficial femoral artery (SFA) is an area of intense research interest and multiple options for treatment. In this Q&A, Gary Ansel, MD, FACC, explains the takeaways from recently released data on various devices and therapies. Dr Ansel is an interventional cardiologist at Riverside Methodist Hospital in Columbus, Ohio, and he is a faculty member… Read More »

Xarelto (rivaroxaban) reduces risk of major amputation by 70% in peripheral artery disease patients

 Bayer and its cooperation partner Janssen Research & Development have announced two publications of further data from the Phase III COMPASS study in The Lancet, one in patients with peripheral artery disease (PAD) and the other in patients with coronary artery disease (CAD). Findings from the PAD analysis showed that rivaroxaban (Xarelto) vascular dose, 2.5mg twice… Read More »

Precommercialisation of Serpentis drug-eluting stent announced

Stentys has announced the precommercialisation of its Serpentis stent. According to a press release, the sirolimus-eluting stent has a biodegradable coating and is designed for routine procedures. Now that the device has the CE mark, Stentys plans for the stent to be precommercialised by the end of the year to a selection of pilot centres… Read More »

Positive 24-month TOBA Results

  Intact Vascular has announced that positive single centre twenty-four month results from its TOBA(Tack optimised balloon angioplasty) clinical study were presented at VEITHsymposium 2017 by Christian Wissgott, assistant director, Westküstenklinikum Heide in Heide, Germany. The multicentre TOBA study enrolled 138 patients with femoropopliteal peripheral arterial disease in Europe. All participants underwent percutaneous balloon angioplasty and repair of… Read More »

CMS Decision May Threaten DCB Utilization

 Hello and welcome to the November edition of Vascular Disease Management. There are excellent articles in this edition, but I’ve chosen to deviate from the standard practice of commenting on one of these articles. I have instead decided to comment on drug-coated balloon (DCB) technology as there are now 3 FDA-approved devices, with many others… Read More »

Serranator Alto serration balloon effective at 30 days in treating critical femoropopliteal lesion

Preliminary 30-day data from the PRELUDE trial investigating the use of the Serranator Alto percutaneous transluminal angioplasty (PTA) serration balloon catheter (Cagent Vascular) have shown 100% technical success and good effectiveness in moderate to severe calcification in the superficial femoral artery. The acute results show that the balloon can achieve low residual stenosis, and final… Read More »

To Save Limbs, A Multi-Disciplinary Approach is Vital

The loss of a limb has a devastating impact on individuals and can be a death sentence in some parts of the world. Treating patients with complex medical needs is challenging though, and clinicians are most likely to successfully prevent amputation and its repercussions by working as part of a multidisciplinary team. In this Q&A,… Read More »